StreetAlpha.app
Home › Stocks › DXCM

Dexcom Inc (DXCM)

Healthcare
$82.04
▲ +0.53%
LAST CLOSE · NOV 17

Dexcom makes continuous glucose monitoring systems that track blood sugar for people with diabetes and others. It last closed at $82.04 on Nov 17, up 0.53% on the day. DXCM reports earnings on Thu, Feb 11, 2027. The average 12-month price target from 8 analysts is $100.63 (+22.7% from the last close), with a high of $120.00 and a low of $85.00. Analyst consensus is Strong Buy, based on the latest ratings from 8 firms (7 buy, 1 hold, 0 sell). Over the past 90 days StreetAlpha recorded 9 whale options trades in DXCM, 67% of them bullish and 33% bearish. In the past 30 days there were 4 dark pool prints totaling $4.3M, the largest $2.5M.

AI Auto Pilots
Is DXCM in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$5.1B
+13.0% vs a year ago
Net income
$991.0M
+37.5% vs a year ago
EPS (diluted)
$2.54
+41.1% vs a year ago
Free cash flow
$1.1B
21.5% margin
Valuation
Market cap
$30.6B
373.0M shares
P/E
32.3
Price over 12 month EPS
Price to sales
6.0
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$961.4M
At Sep 30
Debt
$1.2B
At Sep 30
Shareholder equity
$2.5B
Buybacks
$1.3B
Last 12 months
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $2.4B$2.4BFY2021FY2022: $2.9B$2.9BFY2022FY2023: $3.6B$3.6BFY2023FY2024: $4.0B$4.0BFY2024FY2025: $4.7B$4.7BFY2025

From DXCM's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 29). Last 12 months adds up the four latest quarters.

Next report
Feb 11
2027 · Time not announced
Consensus EPS forecast
$0.71
$1.38B revenue est.
Year-ago EPS
—
Not on file
Options-implied move
—
Posted about a week before
Analyst consensus
Strong Buy
Based on 8 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
8firms
7 Buy1 Hold0 Sell
Each firm's latest rating on DXCM in the past 90 days
Average 12-month target
$100.63
▲ 22.7% upside

Based on 8 analysts who set a price target on DXCM in the past 90 days. The average target is $100.63, with a high of $120.00 and a low of $85.00, compared with the last close of $82.04.

Low $85.00Avg $100.63High $120.00
Blue marker: last close $82.04
Highest target$120.00
Average target$100.63
Lowest target$85.00
Latest rating changes
UBSTarget raised
Oct 31Buy$96 → $107
Canaccord GenuityTarget raised
Oct 31Buy$90 → $97
JP MorganTarget raised
Oct 30Hold$82 → $85
BarclaysTarget raised
Oct 30Buy$115 → $120
StoneXMaintained
Oct 30Buy$93
DateFirmActionRatingPrice target
Oct 31UBSTarget raisedBuy$96 → $107
Oct 31Canaccord GenuityTarget raisedBuy$90 → $97
Oct 30JP MorganTarget raisedHold$82 → $85
Oct 30BarclaysTarget raisedBuy$115 → $120
Oct 30StoneXMaintainedBuy$93
Loading…

Technical Analysis

DXCM · as of the Nov 17 close · updated after every close
Moving sideways

The stock sits between its 20 and 50 day averages. It is 8% above its 200 day average, so the longer trend is still up. Momentum is improving (RSI 49). The nearest support is the 20 day average at $81.21, and the nearest resistance the Pivot at $82.54.

Short trendNeutral
Long trendBullish
MomentumImproving
StretchNormal
VolatilityHigh, 3.5%/day
Key levels
$92.5952 week high+12.9%
$87.70Swing high (Oct 1)+6.9%
$84.1250 day average+2.5%
$83.52Pivot R1+1.8%
$82.82100 day average+1.0%
$82.54Pivot+0.6%
$82.04Last close
$81.2120 day average−1.0%
$81.06Pivot S1−1.2%
$78.93Swing low (Nov 11)−3.8%
$75.17200 day average−8.4%
$56.7252 week low−30.9%
Indicators
RSI (14)48.84Middle of its rangeNeutral
MACD-0.60Above its signal lineBullish
Stochastic35.2Middle of its rangeNeutral
ADX (14)15.4No clear trend
Williams %R-70.4Oversold below −80, overbought above −20Neutral
CCI (20)36.6Oversold below −100, overbought above 100Neutral
Rate of change−1.1%Change over 10 sessionsBearish
ATR (14)$2.87Typical daily range, 3.5% of price
MA 10Below
MA 20Above
MA 50Below
MA 100Below
MA 200Above
What happened before, for DXCM

What happened before

See how DXCM did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Whale flow leans bullish6 bullish and 3 bearish whale options trades in the last 90 days. See Whale Flow
November seasonalityHow DXCM usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How DXCM has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
9
Bullish
6
67%
Bearish
3
33%
Date span
Aug 21 – Nov 12
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
4
Notional
$4.3M
Largest print
$2.5M
Loading…

DXCM Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲543 buying vs 468 selling
  • ▼Held by funds -26.0 pts
  • ▲Funds holding +72
  • ▲Superinvestors: 3 added, 2 cut
  • ▼Put/call 0.37 to 0.49
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding1,064992+7.3%
In funds' top 10106+66.7%
Held by funds105.0%131.0%−26.0 pts
New / increased169 / 374116 / 401+5.0%
Reduced / sold out385 / 83345 / 108+3.3%
Put/call ratio0.490.37+30.6%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See DXCM institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

DXCM Stock Buybacks

See all S&P 500 buybacks →
Spent, 12 months
$1.3B
4.3% yield
Left in program
$400.0M
1.3% of value
Shares outstanding, 12 months
−4.4%
Fewer shares
Last quarter
$400.0M
Sep 2026
Avg price paid, last quarter
$86.32
4.6M shares bought
S&P 500 rank by spending
#150 of 358
 
Spent each quarter, last 3 yearsTop bar $750.0M
Dec 2023: $0Mar 2024: $0Jun 2024: $0Sep 2024: $750.0M, average price $71.90Dec 2024: $0Mar 2025: $0Jun 2025: $0Sep 2025: $187.2M, average price $77.87Dec 2025: $312.7M, average price $59.41Mar 2026: $0Jun 2026: $600.0M, average price $69.88Sep 2026: $400.0M, average price $86.32
Dec 2023Sep 2026
For membersMonth by month buying, shares and the average price paid each month are shown to AI Starter and AI Pro members.

From the company's 10-Q filed Oct 29, 2026. Quarters are the company's own fiscal quarters. Yield and % of value use the latest close. Buybacks are not a forecast: in our testing, the biggest buyers did about the same as the average S&P 500 stock.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether DXCM is in one of them and how their past DXCM trades turned out.

DXCM in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered DXCM in an article yet. Here's the latest on the wider market.

DXCM Congress Trades

All congress trades →
Trades, 12 months
18
Buys
12
67%
Sells
6
33%
People
5
Last filed Sep 22
Who traded DXCM · since 2017
Latest 5 filings of 84
$1K – $15KTraded Jul 17, 2026Filed Sep 22, 2026
$1K – $15KTraded Jun 30, 2026Filed Jul 6, 2026
$1K – $15KTraded May 18, 2026Filed Jul 1, 2026
$100K – $250KTraded May 18, 2026Filed Jul 1, 2026
$1K – $15KTraded May 7, 2026Filed Jun 10, 2026
PersonTypeAmountTradedFiledDelay
Donald J TrumpExecutive branchBuy$1K – $15KJul 17, 2026Sep 22, 202667 d
Ro KhannaD · CASell$1K – $15KJun 30, 2026Jul 6, 20266 d
Donald J TrumpExecutive branchBuy$1K – $15KMay 18, 2026Jul 1, 202644 d
Donald J TrumpExecutive branchBuy$100K – $250KMay 18, 2026Jul 1, 202644 d
Michael McCaulR · TXSell$1K – $15KMay 7, 2026Jun 10, 202634 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Dexcom

Dexcom is a medical device company based in San Diego, California. It designs, makes and sells continuous glucose monitoring systems, which are wearable sensors that track blood sugar without repeated finger sticks. Its main products include the G7 and G7 15 Day systems, the G6, the Dexcom ONE+ and Stelo, a glucose sensor sold without a prescription for adults with prediabetes or Type 2 diabetes who do not use insulin. Its customers include people with diabetes, their caregivers and clinicians, and makers of insulin pumps and pens.

Headquarters
San Diego, CA
Founded
1999